Drugs / Investigational varicella vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06806137 | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06740630 | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06693895 | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational varicella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06806137 ↗ |
| Known as | VNS Vaccine | “GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax.” NCT06693895 ↗2“GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine” NCT06806137 ↗ “three different lots of GSK's investigational varicella vaccine (VNS Vaccine)” NCT06740630 ↗ |
| Modality | Vaccine | “investigational varicella vaccine (VNS Vaccine)” NCT06693895 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06693895 ↗ |